IP Library Granted Patent US 12,606,872
Granted Patent B2
US 12,606,872 · App. 18/096,337 · Granted Apr 21, 2026

Methods for stratification and early detection of advanced adenoma and/or colorectal cancer using DNA methylation markers

Inventors: Pol Canal Noguer (Seville, ES); Juan Carlos Higareda Almaraz (Ljubljana, SI); Francesco Mattia Mancuso (Seville, ES); Kristi Kruusmaa (Ljubljana, SI); Alejandro Requena Bermejo (Seville, ES); Marko Chersicola (Ljubljana, SI); Pablo Pérez Martínez (Seville, ES); Pablo Antonio Camino Faillace (Seville, ES); Primož Knap (Ljubljana, SI); Vivian Erklavec Zajec (Ljubljana, SI); Špela Zavodnik (Ljubljana, SI); Carme Nolla Colomer (Seville, ES); Fernando Trincado Alonso (Seville, ES)
Assignee: Universal Diagnostics, S.A.
C12Q1/6886C12Q2600/112C12Q2600/154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,606,872
App. No.
18/096,337
Granted
Apr 21, 2026
Kind
B2
Abstract

The present disclosure provides for, among other things, methods and systems for detecting, diagnosing, predicting, monitoring, screening for, staging, and/or providing survival prognosis for advanced adenoma and/or colorectal cancer using DNA methylation markers. For example, described herein are DNA methylation markers that enable categorization and prognosis evaluation of advanced adenoma (AA) and/or colorectal cancer (CRC) patients with high accuracy from human biospecimens.

Claims (19)

1 . A method of detecting methylation statuses of markers, the method comprising:

converting unmethylated cytosines of a plurality of DNA fragments in a sample into uracils to generate a plurality of converted DNA fragments, wherein the plurality of DNA fragments were obtained from a biological sample;

sequencing the plurality of converted DNA fragments to generate a plurality of sequence reads, wherein each sequence read corresponds to a converted DNA fragment; and

detecting a methylation status for each of three or more markers identified in the sequence reads,

wherein a first of the three or more markers is a methylation locus comprising at least a portion of SEQ ID NO. 1, a second of the three or more markers is a methylation locus comprising at least a portion of SEQ ID NO. 2, and a third of the three or more markers is a methylation locus comprising at least a portion of SEQ ID NO. 3.

2 . The method of claim 1 , wherein the plurality of DNA fragments (in total) comprise at least 1 ng of DNA.

3 . The method of claim 1 , wherein the plurality of DNA fragments consist essentially of DNA fragments each of which has a length in a range from 10 bp to 800 bp.

4 . The method of claim 1 , wherein the plurality of DNA fragments consist essentially of DNA fragments each of which has a length in a range from 1000 bp to 200,000 bp.

5 . The method of claim 1 , wherein each of the plurality of sequence reads is at least 50 bp.

6 . The method of claim 1 , wherein the method further comprises detecting a methylation status for a fourth methylation locus comprising at least a portion of SEQ ID NO. 70 and a fifth methylation locus comprising at least a portion of SEQ ID NO. 72.

7 . A method of detecting methylation statuses of markers, the method comprising:

converting unmethylated cytosines of a plurality of DNA fragments in a sample into uracils to generate a plurality of converted DNA fragments, wherein the plurality of DNA fragments were obtained from a biological sample;

sequencing the plurality of converted DNA fragments to generate a plurality of sequence reads, wherein each sequence read corresponds to a converted DNA fragment; and

detecting a methylation status for each of two or more markers identified in the sequence reads,

wherein a first of the two or more markers is a methylation locus comprising at least a portion of SEQ ID NO. 70 and a second of the two or more markers is a methylation locus comprising at least a portion of SEQ ID NO. 72.

8 . The method of claim 7 , wherein the plurality of DNA fragments (in total) comprise at least 1 ng of DNA.

9 . The method of claim 7 , wherein the plurality of DNA fragments consist essentially of DNA fragments each of which has a length in a range from 10 bp to 800 bp.

10 . The method of claim 7 , wherein the plurality of DNA fragments consist essentially of DNA fragments each of which has a length in a range from 1000 bp to 200,000 bp.

11 . The method of claim 7 , wherein each of the plurality of sequence reads is at least 50 bp.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2023
From: NOGUER, POL CANAL; HIGAREDA ALMARAZ, JUAN CARLOS; MANCUSO, FRANCESCO MATTIA; KRUUSMAA, KRISTI; BERMEJO, ALEJANDRO REQUENA; CHERSICOLA, MARKO; MARTÍNEZ, PABLO PÉREZ; CAMINO FAILLACE, PABLO ANTONIO; KNAP, PRIMOZ; ZAJEC, VIVIAN ERKLAVEC; ZAVODNIK, ¿PELA; COLOMER, CARME NOLLA; ALONSO, FERNANDO TRINCADO
To: UNIVERSAL DIAGNOSTICS, S.A.
Reel/Frame 063882/0924 →
Continuity (2)
Provisional Application 63425882 · Nov 16, 2022
Related Publication 20240158862A1 · May 16, 2024
References Cited (278)
US 6265171B1 · Herman et al. · 2001 [cited by applicant]
US 6605432B1 · Huang · 2003 [cited by applicant]
US 6812339B1 · Venter et al. · 2004 [cited by applicant]
US 7144701B2 · Huang · 2006 [cited by applicant]
US 7745391B2 · Mintz et al. · 2010 [cited by applicant]
US 7807358B1 · Huang · 2010 [cited by applicant]
US 8048634B2 · Lai · 2011 [cited by applicant]
US 9745622B2 · An et al. · 2017 [cited by applicant]
US 9850523B1 · Chudova et al. · 2017 [cited by applicant]
US 10006925B2 · Bitenc et al. · 2018 [cited by applicant]
US 10301680B2 · Ahlquist et al. · 2019 [cited by applicant]
US 10392666B2 · Lo et al. · 2019 [cited by applicant]
US 10428388B2 · An et al. · 2019 [cited by applicant]
US 11001898B2 · Bitenc et al. · 2021 [cited by applicant]
US 11118228B2 · Allawi et al. · 2021 [cited by applicant]
US 11345967B2 · Morris · 2022 [cited by applicant]
US 11396679B2 · Bitenc et al. · 2022 [cited by applicant]
US 11530453B2 · Bitenc et al. · 2022 [cited by applicant]
US 11728007B2 · Ghosh · 2023 [cited by applicant]
US 11773453B2 · Talasaz · 2023 [cited by applicant]
US 11827942B2 · Mortimer et al. · 2023 [cited by applicant]
US 11869661B2 · Maher · 2024 [cited by applicant]
US 11879158B2 · Talasaz · 2024 [cited by applicant]
US 11898199B2 · Bitenc et al. · 2024 [cited by applicant]
US 11929148B2 · Filippova et al. · 2024 [cited by applicant]
US 20070237813A1 · Misawa et al. · 2007 [cited by applicant]
US 20070298506A1 · Ordway et al. · 2007 [cited by applicant]
US 20100167940A1 · Feinberg · 2010 [cited by applicant]
US 20100240549A1 · Brown · 2010 [cited by applicant]
US 20100298158A1 · DePinho et al. · 2010 [cited by applicant]
US 20110318738A1 · Jones et al. · 2011 [cited by applicant]
US 20120289581A1 · Chang et al. · 2012 [cited by applicant]
US 20130012410A1 · Zou et al. · 2013 [cited by applicant]
US 20130085681A1 · Deciu et al. · 2013 [cited by applicant]
US 20130189684A1 · Ehrich et al. · 2013 [cited by applicant]
US 20130288247A1 · Mori et al. · 2013 [cited by applicant]
US 20140128283A1 · Feinberg et al. · 2014 [cited by applicant]
US 20150011403A1 · Lo et al. · 2015 [cited by applicant]
US 20150072866A1 · Weisburg et al. · 2015 [cited by applicant]
US 20150152505A1 · Lapointe et al. · 2015 [cited by applicant]
US 20160333416A1 · Babiarz et al. · 2016 [cited by applicant]
US 20160355885A1 · Weinhausel et al. · 2016 [cited by applicant]
US 20170016048A1 · Blauwkamp et al. · 2017 [cited by applicant]
US 20170101674A1 · So et al. · 2017 [cited by applicant]
US 20170298439A1 · Ahlquist et al. · 2017 [cited by applicant]
US 20170335401A1 · Allawi et al. · 2017 [cited by applicant]
US 20170356051A1 · Ishioka et al. · 2017 [cited by applicant]
US 20170369948A1 · Markowitz et al. · 2017 [cited by applicant]
US 20180051338A1 · West et al. · 2018 [cited by applicant]
US 20180119137A1 · Matsuguchi et al. · 2018 [cited by applicant]
US 20180148777A1 · Kirkizlar et al. · 2018 [cited by applicant]
US 20180245157A1 · Allawi et al. · 2018 [cited by applicant]
US 20180251859A1 · Ahlquist et al. · 2018 [cited by applicant]
US 20180258498A1 · Ahlquist et al. · 2018 [cited by applicant]
US 20180305765A1 · Feber et al. · 2018 [cited by applicant]
US 20180363063A1 · Guerrero-Preston et al. · 2018 [cited by applicant]
US 20190025308A1 · Cummings et al. · 2019 [cited by applicant]
US 20190032149A1 · Van Engeland et al. · 2019 [cited by applicant]
US 20190085406A1 · Mortimer et al. · 2019 [cited by applicant]
US 20190112645A1 · Woodhouse et al. · 2019 [cited by applicant]
US 20190161805A1 · Ahlquist et al. · 2019 [cited by applicant]
US 20190161806A1 · Ahlquist et al. · 2019 [cited by applicant]
US 20190256921A1 · Mueller et al. · 2019 [cited by applicant]
US 20190256924A1 · Vogelstein et al. · 2019 [cited by applicant]
US 20190352721A1 · Kusunoki et al. · 2019 [cited by applicant]
US 20200017916A1 · Ren · 2020 [cited by applicant]
US 20200131582A1 · Zhou et al. · 2020 [cited by applicant]
US 20200157640A1 · Letourneur et al. · 2020 [cited by applicant]
US 20200340062A1 · Salhia · 2020 [cited by applicant]
US 20200377954A1 · Bitenc et al. · 2020 [cited by applicant]
US 20200377959A1 · Bitenc et al. · 2020 [cited by applicant]
US 20210017605A1 · Jaimovich et al. · 2021 [cited by applicant]
US 20210139948A1 · Bitenc et al. · 2021 [cited by applicant]
US 20210230707A1 · Bitenc et al. · 2021 [cited by applicant]
US 20210277487A1 · Bitenc et al. · 2021 [cited by applicant]
US 20210324477A1 · Xiang et al. · 2021 [cited by applicant]
US 20210332440A1 · Kruusmaa et al. · 2021 [cited by applicant]
US 20210355542A1 · Bitenc et al. · 2021 [cited by applicant]
US 20210404010A1 · Bitenc et al. · 2021 [cited by applicant]
US 20210404011A1 · Bitenc et al. · 2021 [cited by applicant]
US 20220106644A1 · Taylor et al. · 2022 [cited by applicant]
US 20220136058A1 · Allawi et al. · 2022 [cited by applicant]
US 20220186323A1 · Mortimer et al. · 2022 [cited by applicant]
US 20220228221A1 · Curtis · 2022 [cited by applicant]
US 20220389521A1 · Bitenc et al. · 2022 [cited by applicant]
US 20220403471A1 · Morris et al. · 2022 [cited by applicant]
US 20220403473A1 · Lewin et al. · 2022 [cited by applicant]
US 20220411878A1 · Kruusmaa · 2022 [cited by applicant]
US 20230028856A1 · Ahlquist et al. · 2023 [cited by applicant]
US 20230090925A1 · Liu · 2023 [cited by applicant]
US 20230175058A1 · Delubac et al. · 2023 [cited by applicant]
US 20230178181A1 · Mahajan et al. · 2023 [cited by applicant]
US 20230183815A1 · Bitenc et al. · 2023 [cited by applicant]
US 20230193395A1 · Liu et al. · 2023 [cited by applicant]
US 20230203473A1 · Diniz De Carvalho et al. · 2023 [cited by applicant]
US 20230220492A1 · St. John et al. · 2023 [cited by applicant]
US 20230242995A1 · Van Engeland et al. · 2023 [cited by applicant]
US 20230323446A1 · Ariazi et al. · 2023 [cited by applicant]
US 20240060143A1 · Yip et al. · 2024 [cited by applicant]
US 20240084397A1 · Mahajan et al. · 2024 [cited by applicant]
US 20240279746A1 · Bitenc et al. · 2024 [cited by applicant]
CA 3236697A1 · 2023 [cited by applicant]
EP 2481813A1 · 2012 [cited by applicant]
EP 2497834A2 · 2012 [cited by applicant]
EP 2886659A1 · 2015 [cited by applicant]
EP 2899275A1 · 2015 [cited by applicant]
EP 2977467A2 · 2016 [cited by applicant]
EP 4022093A1 · 2022 [cited by applicant]
WO WO02081749A2 · 2002 [cited by applicant]
WO WO2005001142A2 · 2005 [cited by applicant]
WO WO2007149269A2 · 2007 [cited by applicant]
WO WO2010118559A1 · 2010 [cited by applicant]
WO WO2012034170A1 · 2012 [cited by applicant]
WO WO2012047899A2 · 2012 [cited by applicant]
WO WO2012104642A1 · 2012 [cited by applicant]
WO WO2012154979A2 · 2012 [cited by applicant]
WO WO2012167145A2 · 2012 [cited by applicant]
WO WO2012170715A1 · 2012 [cited by applicant]
WO WO2013057581A2 · 2013 [cited by applicant]
WO WO2013097868A1 · 2013 [cited by applicant]
WO WO2014032227A1 · 2014 [cited by applicant]
WO WO2014062218A1 · 2014 [cited by applicant]
WO WO2015116837A1 · 2015 [cited by applicant]
WO WO2015153283A1 · 2015 [cited by applicant]
WO WO2015153284A1 · 2015 [cited by applicant]
WO WO2015159292A2 · 2015 [cited by applicant]
WO WO2016011021A1 · 2016 [cited by applicant]
WO WO2016060278A1 · 2016 [cited by applicant]
WO WO2016109782A2 · 2016 [cited by applicant]
WO WO2017012592A1 · 2017 [cited by applicant]
WO WO2017043497A1 · 2017 [cited by applicant]
WO WO2017048932A1 · 2017 [cited by applicant]
WO WO2017192221A1 · 2017 [cited by applicant]
WO WO2017201606A1 · 2017 [cited by applicant]
WO WO2017212428A1 · 2017 [cited by applicant]
WO WO2018087129A1 · 2018 [cited by applicant]
WO WO2018119452A2 · 2018 [cited by applicant]
WO WO2018140781A1 · 2018 [cited by applicant]
WO WO2018195211A1 · 2018 [cited by applicant]
WO WO2018209361A2 · 2018 [cited by applicant]
WO WO2019068082A1 · 2019 [cited by applicant]
WO WO2019175876A2 · 2019 [cited by applicant]
WO WO2020069350A1 · 2020 [cited by applicant]
WO WO2020163410A1 · 2020 [cited by applicant]
WO WO2020232109A1 · 2020 [cited by applicant]
WO WO2020239895A2 · 2020 [cited by applicant]
WO WO2020239896A1 · 2020 [cited by applicant]
WO WO2021016441A1 · 2021 [cited by applicant]
WO WO2021041726A1 · 2021 [cited by applicant]
WO WO2021094017A1 · 2021 [cited by examiner]
WO WO2021202351A1 · 2021 [cited by applicant]
WO WO2021209161A1 · 2021 [cited by applicant]
WO WO2021216477A1 · 2021 [cited by applicant]
WO WO2021228418A1 · 2021 [cited by applicant]
WO WO2022002423A1 · 2022 [cited by applicant]
WO WO2022002424 · 2022 [cited by applicant]
WO WO2022003572A1 · 2022 [cited by applicant]
WO WO2022238559A1 · 2022 [cited by applicant]
WO WO2022238560A1 · 2022 [cited by applicant]
WO WO2023023123A1 · 2023 [cited by applicant]
WO WO2023083308A1 · 2023 [cited by applicant]
Moser et al., “Targeted bisulfite sequencing: A novel tool for the assessment of DNA methylation with high sensitivity and increased coverage,” Psychoneuroendocrinology, vol. 120, pp. 1-8. (Year: 2020). [cited by examiner]
Su et al., “FGF14 is a Functional Tumor Suppressor Through Inhibiting PI3K/ AKT/MTOR Pathway in Colorectal Cancer,” Gut, vol. 68, A15. (Year: 2019). [cited by examiner]
Wu et al., “A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer,” Molecular Oncology, vol. 15, pp. 2702-2714. (Year: 2021). [cited by examiner]
Chiou et al., “Methylation-based enrichment facilitates low-cost, noninvasive genomic scale sequencing of populations from feces,” Scientific Reports, vol. 8, pp. 1-10. (Year: 2018). [cited by examiner]
GENECARDS, GAD2 Gene—Glutamate Decarboxylase 2, 31 pages, (2023). [cited by applicant]
GENECARDS, MYO3A Gene—Myosin IIIA, 29 pages, (2023). [cited by applicant]
UCSC Genome Browser 3, CpG Island Info, Band 10p12.1, 2 pages, (2022). [cited by applicant]
UCSC Genome Browser 4, CpG Island Info, Band 20q13.31, 2 pages, (2022). [cited by applicant]
Aberle, D.R., et al., Reduced lung-cancer mortality with low-dose computed tomographic screening, New England Journal of Medicine, 365(5):395-409, (2011). [cited by applicant]
Adalsteinsson, V.A. et al., Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors, Nat. Commun., 8(1):1324, (2017). [cited by applicant]
Adler, A. et al., Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany, BMC Gastroenterology, 14:183, (2014). [cited by applicant]
Adusumalli, S. et al., Methodological aspects of whole-genome bisulfite sequencing analysis, Briefings in Bioinformatics, 16(3):369-379, (2014). [cited by applicant]
Andersson, I., et al., Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial, British Medical Journal, 297(6654): 943-8, (1988). [cited by applicant]
Bacolod, M. D. et al., Application of Multiplex Bisulfite PCR-Ligase Detection Reaction-Real-Time Quantitative PCR Assay in Interrogating Bioinformatically Identified, Blood-Based Methylation Markers for Colorectal Canc… [cited by applicant]
Beikircher, G. et al., Multiplexed and Sensitive DNA Methylation Testing Using Methylation-Sensitive Restriction Enzymes “MSRE-qPCR”, DNA Methylation Protocols, Methods in Molecular Biology 1708:Ch21:407-424, (2018). [cited by applicant]
Blesa, J. R. et al., NRF-1 is the major transcription factor regulating the expression of the human TOMM34 gene, Biochemistry and Cell Biology, 86(1):46-56, (2008). [cited by applicant]
Bray, F. et al., Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J Clin., 68:394-424, (2018). [cited by applicant]
Breast Cancer Screening (PDQ®)-Health Professional Version, <https://www.cancer.gov/types/breast/hp/breast-screening-pdq#section/all>. Retrieved on Jul. 17, 2020. [cited by applicant]
Calderwood, A. H. et al., Colon adenoma features and their impact on risk of future advanced adenomas and colorectal cancer, World Journal of Gastrointestinal Oncology, 8(12):826-834, (2016). [cited by applicant]
Campan, M. et al., MethyLight and Digital MethyLight, DNA Methylation Protocols, Methods in Molecular Biology, 1708:CH25:497-513, (2018). [cited by applicant]
Chang, C. P.-Y. et al., Elevated cell-free serum DNA detected in patients with myocardial infarction, Clinica Chimica Acta 327:95-101, (2003). [cited by applicant]
Chen, J. et. al., DNA methylation biomakers in stool for early screening of colorectal cancer, Journal of Cancer,10(21):5264-5271, (2019). [cited by applicant]
Chen, J.J., et. al., DNA methylation assay for colorectal carcinoma, Cancer Biology & Medicine, 14(1):42-49, (2017). [cited by applicant]
Chen, Y. et al., Tissue-independent and tissue-specific patterns of DNA methylation alteration in cancer, Epigenetics & Chromatin, 9:10, (2016). [cited by applicant]
Chiu, R. W. K. et al., Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma, PNAS, 105(51):20458-20463, (2008). [cited by applicant]
Demissie, K., et al., Empirical comparison of the results of randomized controlled trials and case-control studies in evaluating the effectiveness of screening mammography, J. Clin. Epidemiol., 51(2):81-91, (1998). [cited by applicant]
DOE Joint Genome Institute, AC012313, (2003). [cited by applicant]
DOE Joint Genome Institute, AC024563, (2002). [cited by applicant]
Esteller, M., CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future, Oncogene, 21:5427-5440, (2002). [cited by applicant]
Exner, R. et al., Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers, Br. J. Cancer, 113(7):1035-1045 (2015). [cited by applicant]
Fackler, M. J. and Sukumar, S., Quantitation of DNA Methylation by Quantitative Multiplex Methylation-Specific PCR (QM-MSP) Assay, DNA Methylation Protocols, Methods in Molecular Biology, 1708:CH24:473-496, (2018). [cited by applicant]
Fan, C.H.. et al., Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood, Proceedings of The National Academy of Sciences, 105(42):16266-16271 (2008). [cited by applicant]
Frommer, M. et al., A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands, Proc. Natl. Acad. Sci. USA, 89:1827-1831, (1992). [cited by applicant]
Galanopoulos, M., et. al., Abnormal DNA methylation as a cell-free circulating DNA biomarker for colorectal cancer detection: A review of literature, World Journal of Gastrointestinal Oncology, 9(4):142-152, (2017). [cited by applicant]
Galeazzi, M. et al., Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders, Autoimmunity Reviews, 2:50-55, (2003). [cited by applicant]
Gasc, C. et al., Survey and Summary: Sequence capture by hybridization to explore modern and ancient genomic diversity in model and nonmodel organisms, Nucleic Acids Research, 44(10):4504-4518, (2016). [cited by applicant]
Genecards, ALKAL1 Gene—ALK and LTK Ligand 1, 18 pages, (2022). [cited by applicant]
Gibson, J.A. and Odze, R.D., Pathology of premalignant colorectal neoplasia, Dig. Endosc., 28(3):312-323 (2016). [cited by applicant]
Gonzalgo, M. L. and Liang, G., Methylation-sensitive single-nucleotide primer extension (Ms-SNuPE) for quantitative measurement of DNA methylation, Nature Protocols, 2(8):1931-1936, (2007). [cited by applicant]
Heidary, M. et al., The dynamic range of circulating tumor DNA in metastatic breast cancer, Breast Cancer Res., 16(4):421, (2014). [cited by applicant]
Hemmasi, G., et al., Prevalence of colorectal adenoma in an average-risk population aged 40-50 versus 50-60 years, European Journal of Cancer Prevention (ECP), pp. 1-5, (2014). [cited by applicant]
Herman, J. G. et al., Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands, Proc. Natl. Acad. Sci. USA, 93:9821-9826, (1996). [cited by applicant]
Hussmann, D. and Hansen, L. L., Methylation-Sensitive High Resolution Melting (MS-HRM), DNA Methylation Protocols, Methods in Molecular Biology, 1708:CH28:551-571, (2018). [cited by applicant]
Imperiale, T. F. et al., Multitarget Stool DNA Testing for Colorectal-Cancer Screening, Correspondence to the Editor, The New England Journal of Medicine, doi:10.1056/NEJMc1405215, 371(2):184-188, (2014). [cited by applicant]
Imperiale, T. F. et al., Multitarget Stool DNA Testing for Colorectal-Cancer Screening, The New England Journal of Medicine, 370(14):1287-1297, (2014). [cited by applicant]
Ivanov, M. et al., In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes, Nucleic Acids Research, 46(6):e72, 9 pages, (2013). [cited by applicant]
Karsenti, D. et al., Adenoma and advanced neoplasia detection rates increase from 45 years of age, World Journal of Gastroenterology, 25(4): 447-456 (2019). [cited by applicant]
Kirkizlar, E. et al., Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology, Transl. Oncol., 8(5):407-416, (2015). [cited by applicant]
Kok-Sin, T., et. al., Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data, Oncology Reports, 34:22-32, (2015). [cited by applicant]
Kordowski., F., et al., Aberrant DNA methylation of ADAMTS16 in colorectal and other epithelial cancers, BMC Cancer, 18(1):4, (2018). [cited by applicant]
Krueger, F. and Andrews, S.R., Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications, Bioinformatics, 27(11):1571-2, (2011). [cited by applicant]
Kruusmaa, K. et. al., MSRE-qPCR for analysis of gene specific methylation can be accurately used for detection and validation of colorectal cancer-specific patterns, 4Bio Summit (Jan. 1, 2018). <www.universaldx.com/wp-c… [cited by applicant]
Kukita, Y. et al., High-fidelity target sequencing of individual molecules identified using barcode sequences: de novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients, DNA R… [cited by applicant]
Kutsenko, A., et. al., Notl flanking sequences: a tool for gene discovery and verification of the human genome, Nucleic Acids Research, 30(14):3163-3170, (2002). [cited by applicant]
Laird, P. W., Applications of Next-Generation Sequencing: Principles and challenges of genomewide DNA methylation analysis, Nature Review Genetics, 11:191-203, (2010). [cited by applicant]
Lam, K. et al., DNA methylation based biomakers in colorectal cancer: A systematic review, Elsevier Science BV, Biochimica et Biophysica Acta 1866:106-1202 (2016). [cited by applicant]
Leary, R.J. et al., Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing, Sci. Transl. Med., 4(162):162ra154, (2012). [cited by applicant]
Leon, S. A. et al., Free DNA in the Serum of Cancer Patients and the Effect of Therapy, Cancer Research, 37:646-650, (1977). [cited by applicant]
Li, H. et. al., Identification of novel DNA methylation markers in colorectal cancer using MIRA-based microarrays, Oncology Reports, 28(1):99-104, (2012). [cited by applicant]
Lianidou, E., Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook, Mol. Oncol., 15(6):1683-1700, (2021). [cited by applicant]
Liles, E. G. et al., Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial, Cancer Treatment and Research Communications, 10:27-31, (2017). [cited by applicant]
Liu, W-B et al., TMEM196 acts as a novel functional tumour suppressor inactivated by DNA methylation and is a potential prognostic biomarker in lung cancer, Oncotarget, 6(25):21225-21239, (2015). [cited by applicant]
Liu, Y. et al., Methylation-sensitive enrichment of minor DNA alleles using a double-strand DNA-specific nuclease, Nucleic Acids Research, 45(6):e39, 11 pages, (2017). [cited by applicant]
Lowe, T., et. al., A Computer program for selection of oligonucleotide primers for polymerase chain reactions, Nucleic Acids Research. 18(7):1757-1761, (1990). [cited by applicant]
Margolin, G. et al., Robust Detection of DNA Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico Modeling for Blood-Based Diagnostic Development, The Journal of Molecular Diagnostics, 18(2):283-298, (2016). [cited by applicant]
Masser, D. R. et al., Targeted DNA Methylation Analysis by Next-generation Sequencing, Journal of Visualized Experiments, 96:e52488, 11 pages, (2015). [cited by applicant]
Melnikov, A. A., et. al., MSRE-PCR for analysis of gene-specific DNA methylation, Nucleic Acids Research, 33(10): e93-e93, (2015). [cited by applicant]
Meyer, D. et al., Package ‘e1071’, Misc Functions of the Department of Statistics, Probability Theory Group (Formerly: E1071), TU Wien, HTTPS://cran.r-project.org/web/packages/e1071/index.html, 63 pages, (2019). [cited by applicant]
Michels, K.B., The promises and challenges of epigenetic epidemiology, Exp. Gerontol., 45(4):297-301, (2010). [cited by applicant]
Mitchell, S. M. et al., A panel of genes methylated with high frequency in colorectal cancer, BMC Cancer, Biomed Central, London, GB, 14(1):54, 15 pages, (2014). [cited by applicant]
Nakamura, A. et al., Relationship between sodium excretion and pioglitazone-induced edema, Journal of Diabetes Investigation, 1(5):208-211, (2010). [cited by applicant]
Navarro, M. et al., Colorectal cancer population screening programs worldwide in 2016: An Update, World J Gastroenterol, 23(20):3632-3642, (2017). [cited by applicant]
O'Connell B., and Crockett S., The clinical impact of serrated colorectal polyps, Clinical Epidemiology, 9: 113-125 (2017). [cited by applicant]
Oh, T. et al., Genome-Wide Identification and Validation of a Novel Methylation Biomarker, SDC2, for Blood-Based Detection of Colorectal Cancer, The Journal of Molecular Diagnostics, 15(4):498-507, (2013). [cited by applicant]
Perakis, S. et al., Advances in Circulating Tumor DNA Analysis, Adv. Clin. Chem., 80:73-153, (2017). [cited by applicant]
Petko, Z. et al., Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps, Clin. Cancer Res., 11(3):1203-1209 (2005). [cited by applicant]
Potter, N. T. et al., Validation of a Real-Time PCR-Based Qualitative Assay for the Detection of Methylated SEPT9 DNA in Human Plasma, Clinical Chemistry, 60(9):1183-1191, (2014). [cited by applicant]
Pulverer, W. et al., The stem cell signature of CHH/CHG methylation is not present in 271 cancer associated 5′UTR gene regions, Biochimie, 94(11):2345-2352 (2012). [cited by applicant]
QIAamp® Circulating Nucleic Acid Handbook, For concentration and purification of free-circulating DNA, RNA, miRNA, and viral nucleic acids from human plasma, serum, urine, or other cell-free body fluids, Oct. 2019. [cited by applicant]
QIAamp® MinElute® ccfDNA Handbook, For concentration and purification of circulation cell-free DNA from plasma or serum, Jan. 2020. [cited by applicant]
Rahib, L., et. al., Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Research, 74(11):2913-21, (2014). [cited by applicant]
Schwarzenbach, H. et al., Cell-free nucleic acids as biomarkers in cancer patients, Nature Reviews Cancer, 11:426-437, (2011). [cited by applicant]
Shaukat, A. et al., Long-Term Mortality after Screening for Colorectal Cancer, The New England Journal of Medicine, 369(12):1106-1114, (2013). [cited by applicant]
Singh, K. E. et al., Colorectal Cancer Incidence Among Young Adults in California, Journal of Adolescent and Young Adult Oncology, 3(4):176-184, (2014). [cited by applicant]
Snyder, M.W. et al., Cell-free DNA Comprises an In vivo Nucleosome footprint that informs its Tissues-Of-Origin, Cell, 164: pp. 57-68, (2016). [cited by applicant]
Swarup, V. and Rajeswari, M.R., Circulating (cell-free) nucleic acids—A promising, non-invasive tool for early detection of several human diseases, FEBS Letters 581:795-799, (2007). [cited by applicant]
The Cancer Genome Atlas Program, <https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/toga>. Retrieved on Jul. 17, 2020. [cited by applicant]
UCSC Genome Browser 1, CpG Island Info, Band 9p21.3, 2 pages, (2020). [cited by applicant]
UCSC Genome Browser 2, CpG Island Info, Band 8q11.23, 2 pages, (2020). [cited by applicant]
Vainio, H., et al., IARC Handbooks of Cancer Prevention Programme Head: Harri Vainio. vol. 7: Breast Cancer Screening, pp. 1-236, (2002). [cited by applicant]
Van Der Vlugt, M. et al., Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening, British Journal of Cancer, 116(1):44-49, (2017). [cited by applicant]
Wan, M. et al., Identification of Smoking-Associated Differentially Methylated Regions Using Reduced Representation Bisulfite Sequencing and Cell type-Specific Enhancer Activation and Gene Expression, Environ. Health Pe… [cited by applicant]
Wittenberger, T. et al., DNA methylation markers for early detection of women's cancer: promise and challenges, Epigenomics, 6(3):311-327, (2014). [cited by applicant]
Yan, H., et al., Identifying CpG sites with different differential methylation frequencies in colorectal cancer tissues based on individualized differential methylation analysis, Oncotarget, 29(8): 47356-47364, (2017). [cited by applicant]
Yang, Y., et. al., Identification of regulatory role of DNA methylation in colon cancer gene expression via systematic bioinformatics analysis, Medicine, 96(47):1-7, (2017). [cited by applicant]
Zhang, S. et al., CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway, Journal of Experimental and Clinical Cancer Research, 38(1):467, (201… [cited by applicant]
Zhou, X. et al., Identification of epigenetic modulators in human breast cancer by integrated analysis of DNA methylation and RNA-Seq data, Epigenetics, 13(5):473-489, (2018). [cited by applicant]
Estecio, M.R.H. et al., High-throughput methylation profiling by MCA coupled to CpG island microarray, Genome Res., 17(10):1529-1536 (2007). [cited by applicant]
Mori, Y. et al., Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning, Endocr. Relat. Cancer, 18(4):465-478 (2011). [cited by applicant]
Bedin, C. et al., Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients, Int. J. Cancer, 140(8):1888-1898 (2017). [cited by applicant]
International Search Report for PCT/EP2023/081968, 7 pages, (mailed Apr. 10, 2024). [cited by applicant]
Jacob, S.T. and Motiwala, T., Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy, Cancer Gene Ther., 12(8):665-672 (2005). [cited by applicant]
Khamas, A. et al., Genome-wide screening for methylation-silenced genes in colorectal cancer, Int. J. Oncol., 41(2):490-496 (2012). [cited by applicant]
Written Opinion for PCT/EP2023/081968, 12 pages, (mailed Apr. 10, 2024). [cited by applicant]
Ebbert, M.T.W. et al., Evaluating the necessity of PCR duplicate removal from next-generation sequencing data and a comparison of approaches, BMC Bioinformatics, 17(Suppl 7):239 (2016). [cited by applicant]
Fadda, A. et al., Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor, Int. J. Cancer, 143(4):907-920, Sup… [cited by applicant]
Illumina, CpG Loci Identification Technical Note, 2 pages, (2010). [cited by applicant]
Illumina, HumanMethylation450 manifest file (extract), 6 pages, (2008). [cited by applicant]
Illumina, TruSeq DNA Methylation Kit Reference Guide, 40 pages, (2016). [cited by applicant]
Illumina, TruSeq DNA Methylation Library Preparation Guide, 20 pages, (2014). [cited by applicant]
Kruusmaa, K. et al., Development and clinical performance of an accurate cell-free DNA (cfDNA) methylation assay for early detection of colorectal cancer, Poster, 3 pages, (2020). [cited by applicant]
Naumov, V.A. et al., Genome-scale analysis of DNA methylation in colorectal cancer using Infinium HumanMethylation450 BeadChips, Epigenetics, 8(9):921-934 (2013). [cited by applicant]
Olova, N.N. and Andrews, S., Whole Genome Methylation Sequencing via Enzymatic Conversion (EM-seq): Protocol, Data Processing, and Analysis, bioRxiv preprint, 23 pages, (2023). [cited by applicant]
UCSC Genome Browser on Human (GRCh38/hg38), chr4:143,540,989-143,735,008, 1 page, (2013). [cited by applicant]
UCSC Genome Browser on Human (GRCh38/hg38), chr4:143,699,944-143,701,144, 1 page, (2013). [cited by applicant]
UCSC Genome Browser, ZNF132, ADAMTS2 (exons 1 and 2), LONRF2 (exon 1), ZNF542 (exons 1 and 2), ZNF492 (exon 1), 2 pages, (2024). [cited by applicant]
Wood, L.D. et al., The genomic landscapes of human breast and colorectal cancers, Science, 318(5853):1108-1113 (2007). [cited by applicant]